Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated commercial biotechnology company, announced that its management team will participate in two upcoming investor conferences in May 2026: the RBC Capital Markets Global Healthcare Conference on May 19 in New York and A.G.P.'s Annual Virtual Healthcare Conference on May 20. The full press release is available at https://ibn.fm/ZZpG2.
Tonix Pharmaceuticals focuses on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. Its recently approved flagship medicine, TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), is the first new treatment for fibromyalgia in more than 15 years. The company's CNS commercial infrastructure supports its marketed products, including its acute migraine products Zembrace® SymTouch® and Tosymra®. Tonix is also exploring the potential of TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder.
Beyond CNS, Tonix's pipeline includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. In immunology, the company is advancing monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
The participation in these conferences highlights Tonix's commitment to communicating its strategic progress and pipeline developments to the investment community. The RBC Capital Markets Global Healthcare Conference is a prominent event that brings together healthcare investors and executives, while A.G.P.'s Annual Virtual Healthcare Conference provides a platform for virtual engagement with a broad investor base.
For the latest news and updates relating to TNXP, visit the company's newsroom at https://ibn.fm/TNXP.
